178 related articles for article (PubMed ID: 38724504)
1. Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.
Prabhu KS; Ahmad F; Kuttikrishnan S; Leo R; Ali TA; Izadi M; Mateo JM; Alam M; Ahmad A; Al-Shabeeb Akil AS; Bhat AA; Buddenkotte J; Pourkarimi E; Steinhoff M; Uddin S
Cell Death Discov; 2024 May; 10(1):225. PubMed ID: 38724504
[TBL] [Abstract][Full Text] [Related]
2. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Ling YH; Liebes L; Zou Y; Perez-Soler R
J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
[TBL] [Abstract][Full Text] [Related]
3. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Li C; Hu J; Li W; Song G; Shen J
Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
[TBL] [Abstract][Full Text] [Related]
4. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
5. The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy.
Yin Y; Qi X; Qiao Y; Liu H; Yan Z; Li H; Liu Z
Curr Cancer Drug Targets; 2019; 19(1):50-64. PubMed ID: 30289077
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties.
Shao R; Liu S; Liu W; Song C; Liu L; Zhu L; Peng F; Lu Y; Tang H
MedComm (2020); 2024 May; 5(5):e562. PubMed ID: 38737470
[TBL] [Abstract][Full Text] [Related]
7. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells.
Ochoa TA; Rossi A; Woodle ES; Hildeman D; Allman D
J Immunol; 2024 Jan; 212(1):154-164. PubMed ID: 37966267
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells.
Rossi UA; Finocchiaro LME; Glikin GC
Anticancer Agents Med Chem; 2017; 17(5):754-761. PubMed ID: 27677689
[TBL] [Abstract][Full Text] [Related]
9. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
[No Abstract] [Full Text] [Related]
10. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics and chemical library screens reveal a novel SCF
Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS.
Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Begum R; Melosantos R; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
J Clin Endocrinol Metab; 2018 Apr; 103(4):1530-1544. PubMed ID: 29300929
[TBL] [Abstract][Full Text] [Related]
13. 3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
Feng M; Wang J; Sun M; Li G; Li B; Zhang H
Cancer Cell Int; 2021 May; 21(1):279. PubMed ID: 34039348
[TBL] [Abstract][Full Text] [Related]
14. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
[TBL] [Abstract][Full Text] [Related]
15. Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction.
Rong J; Li P; Ge Y; Chen H; Wu J; Zhang R; Lao J; Lou D; Zhang Y
Colloids Surf B Biointerfaces; 2020 Feb; 186():110674. PubMed ID: 31855686
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
17. BNIP3 overexpression may promote myeloma cell apoptosis by enhancing sensitivity to bortezomib via the p38 MAPK pathway.
Xiao P; Chen X; Dong Z; Fan W; Chen Y; Su J; Wang Q; Ma L
Hematology; 2023 Dec; 28(1):2231739. PubMed ID: 37401850
[TBL] [Abstract][Full Text] [Related]
18.
Rani S; Sahoo RK; Kumar V; Chaurasiya A; Kulkarni O; Mahale A; Katke S; Kuche K; Yadav V; Jain S; Nakhate KT; Ajazuddin ; Gupta U
Mol Pharm; 2023 Jan; 20(1):524-544. PubMed ID: 36306447
[TBL] [Abstract][Full Text] [Related]
19. B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.
Hui YJ; Yu TT; Li LG; Peng XC; Di MJ; Liu H; Gu WL; Li TF; Zhao KL; Wang WX
Sci Rep; 2024 Apr; 14(1):7733. PubMed ID: 38565963
[TBL] [Abstract][Full Text] [Related]
20. Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
Hattori K; Takano N; Kazama H; Moriya S; Miyake K; Hiramoto M; Tsukahara K; Miyazawa K
Oncol Lett; 2021 Sep; 22(3):680. PubMed ID: 34345305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
